drugset / Trial / NCT02426099

Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension

NCT02426099

Phase 4 Completed 17 enrolled Sobngwi Eugene University of Yaounde 1 · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a four-week randomized controlled single blinded trial of subjects presenting with resistant hypertension in a specialized diabetes care unit of Cameroon. They are randomly assigned using the method of blocks to treatment with a daily 25mg of spironolactone or to routine intensification of antihypertensive regimen , all added to previous regimen with unchanged diet. Visits are scheduled at the start of the treatment, at weeks two and four following add-on therapy initiation. The primary outcome is change in office and self-measurement blood pressure recorded at each visit, and secondary outcomes are variations in serum potassium, sodium, and creatinine levels.

Timeline

Start
2011-10
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Spironolactone Small molecule 25 mg